Rahman, R.L.; Santillan, A.; Habibi, M.; Beitsch, P.; Whitworth, P.; Ramaswamy, H.; Chmielewski-Stivers, N.; Menicucci, A.; Audeh, W.; O’Shaughnessy, J.
Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision Medicine—Biology Is Still King. Int. J. Mol. Sci. 2025, 26, 491.
https://doi.org/10.3390/ijms26020491
AMA Style
Rahman RL, Santillan A, Habibi M, Beitsch P, Whitworth P, Ramaswamy H, Chmielewski-Stivers N, Menicucci A, Audeh W, O’Shaughnessy J.
Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision Medicine—Biology Is Still King. International Journal of Molecular Sciences. 2025; 26(2):491.
https://doi.org/10.3390/ijms26020491
Chicago/Turabian Style
Rahman, Rakhshanda Layeequr, Alfredo Santillan, Mehran Habibi, Peter Beitsch, Pat Whitworth, Harshini Ramaswamy, Nicole Chmielewski-Stivers, Andrea Menicucci, William Audeh, and Joyce O’Shaughnessy.
2025. "Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision Medicine—Biology Is Still King" International Journal of Molecular Sciences 26, no. 2: 491.
https://doi.org/10.3390/ijms26020491
APA Style
Rahman, R. L., Santillan, A., Habibi, M., Beitsch, P., Whitworth, P., Ramaswamy, H., Chmielewski-Stivers, N., Menicucci, A., Audeh, W., & O’Shaughnessy, J.
(2025). Neoadjuvant Chemotherapy for T3 Tumors in the Era of Precision Medicine—Biology Is Still King. International Journal of Molecular Sciences, 26(2), 491.
https://doi.org/10.3390/ijms26020491
